MMP9 and metabolic dysfunction-associated steatohepatitis: A low molecule chymase inhibitor significantly attenuated chymase activity and decreased angiotensin II, MMP-9 and collagen I levels in the liver in an MCD diet-fed NASH hamster model, when administration of the inhibitor was initiated at the same time as the MCD diet (Tashiro et al., 2010; Masubuchi et al., 2013).